Objective: To assess the efficacy and tolerability of the three component drug stalevo in the treatment of patients with Parkinson's disease (PD). Material and methods: We analyzed the experience of using the antiparkinsonian drug stalevo (levodopa/carbidopa/entacapone) in the treatment of acute stages of PD and elderly patients with restricted possibilities of using other antiparkinsonian drugs. The study included 47 patients. A clinical example is presented. Results and сonclusion: Stalevo increased motor and daily activities, reduced the severity of basic symptoms of PD and improved quality of life of the patients.